menu search

CCCC / C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Read More
Posted: Feb 23 2023, 09:47
Author Name: Zacks Investment Research
Views: 110881

CCCC News  

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 4, 2023

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares t more_horizontal

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

By Zacks Investment Research
February 23, 2023

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the more_horizontal

Why C4 Therapeutics Stock Is Plunging Today

By Benzinga
April 8, 2022

Why C4 Therapeutics Stock Is Plunging Today

C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongo more_horizontal

C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial

By Benzinga
April 8, 2022

C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial

C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgk more_horizontal


Search within

Pages Search Results: